
Keywords: مزودرم مضاعف; Pluripotent stem cells; iPS cells; ES cells; Mesoderm specification; Myogenic progenitor; WNT activation; GSK3 inhibitor; Pax3; Pax7; MyoD; Myf5; BMP inhibitor; TGFβ inhibitor; Cell therapy; Disease modeling; Myogenesis; Muscle development; Somite; Parax